AtriCure, Inc. reported second quarter 2026 financial results with worldwide revenue of $153.6 million, a 12.8% year-over-year increase. Net income for the period was $9.0 million, compared to a net loss of $6.2 million in the second quarter of 2025. Adjusted EBITDA for the quarter was $27.3 million, up from $15.3 million in the prior year. The company projects full-year 2026 revenue between $602 million and $610 million. AtriCure, Inc. is a medical technology company specializing in surgical treatments for atrial fibrillation and related conditions.